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INTRODUCTION
We are in the midst of the novel coronavirus (COVID-19) pandemic, the most significant global
health event since Spanish influenza in the early 20th century. Increasingly draconian measures
are being implemented worldwide to try to slow the spread of the virus. Antimicrobial resistance
(AMR) has been cited as the most significant threat to the global health and global economy in
recent years, but is now likely to be eclipsed by COVID-19 for some time. However, the emergence
of COVID-19 also presents some important consequences for the development of AMR. This piece
will highlight how managing the COVID-19 crisis could impact AMR in the clinic, beyond the
clinic in the community, in the environment and in relation to public awareness. When civilization
emerges from the other side of this global health emergency, efforts should be made to understand
these potential effects on AMR, the other significant, and constant global health issue of our time.
In the Clinic
Healthcare systems around the world are under increasingly immense pressure. This is leading to
several changes in practice that may have impacts on, or relevance to, AMR.
For example, the UK government have published several documents relating to COVID-19
management in clinical settings. In the guidance for primary care, it is recommended that any room
that has been used for a patient with a suspected SARS-CoV-2 (the causative agent of COVID-19)
infection should remain closed and ventilation switched off until full sterilization has taken place
(HM Government, 2020a). With regards to infection prevention and control procedure, additional
measures are recommended regarding transmission prevention. These include precautions around
direct contact with potentially contaminated surfaces, droplets and aerosols (HM Government,
2020b). These may not become routine management options within clinical settings following the
COVID-19 pandemic, however, many of these practices may also reduce dissemination of AMR
bacteria at a local and global scale. In particular, extra vigilance around hygiene and additional
sterilization procedures may reduce the spread of AMR bacteria. It would be interesting to gather
data on the prevalence of AMR infections before and after the outbreak to determine if this is the
case. Comparison of whole genome sequences of clinical pathogens before, during and after the
pandemic is one potential technique that could elucidate changes in carriage of AMR mechanisms
circulating in clinical settings. Databases such as BacWGSTdb (Ruan and Feng, 2016) could also be
used to track outbreaks of key AMR pathogens to the species, clonal complex or isolate level.
With regards to COVID-19 patients contracting secondary bacterial infections, there are very
few data so far. However, 1 to 10% of patients have been reported to contract secondary bacterial
infections in two separate studies (Lai et al., 2020). This in comparison to infection with pandemic
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H1N1, where around 12–19% of hospitalized patients with
pneumonia developed secondary bacterial infections (Kim,
2020). Given current data it is not possible to predict whether
the cases of secondary bacterial infection following development
of COVID-19 will increase or decrease overtime. Clinical
microbiologists, as well as radiologists, will be key for making
these distinctions (Kim, 2020). However, despite the relatively
low confirmation of secondary bacterial infections, there have
been comparatively more reports of antibiotic usage when
treating COVID-19 patients (Lai et al., 2020), including up
to 45% of patients receiving antibiotic treatment (Xu et al.,
2020). This is even though the World Health Organization
recommended against the use of antibiotics during COVID-19
treatment (Cascella et al., 2020). It has also been suggested that
certain antibiotics, such as tecioplanin (a glycopeptide antibiotic)
could be used as an antiviral after exhibiting activity against
coronaviruses (amongst others) previously (Baron et al., 2020).
However, great caution should be used given that inappropriate
use or overuse of antibiotics is known to be a significant driver
of the emergence of AMR. This is why significant focus on AMR
revolves around reducing inappropriate or overuse of antibiotics
(NICE, 2018). Countries which have made progress in this area
may face less AMR secondary bacterial infections than countries
that have experienced limited success in reducing antibiotic
consumption. Again, it would be interesting to analyse this data,
when available. The second reason use of antibiotics should be
considered very carefully is that it may lead the public to assume
that all antibiotics are suitable for treatment of viral infections
(see “Public Awareness,” below).
Beyond the Clinic
Outside the clinic, countries are employing measures aimed
at reducing transmission of COVID-19 that range from social
distancing, to full-on lock down and closing borders. One piece
of advice to the public that has remained constant from the
beginning, however, is for the public to regularly wash their
hands with soap and water (or to use hand sanitiser, when these
are unavailable).
Use of antimicrobial soaps and disinfectant cleaners by
members of the community and in the hospital will have
increased hugely over the last few months. Higher usage is
likely to continue, and may even remain high following the
outbreak due to changes in infection and control policy or
individual habits. As discussed above, these increased/improved
hygiene practices may reduce the spread of AMR, which is a
very positive outcome. However, there is also a potential negative
impact that could arise from increased use of such products,
as many of them contain biocides. Biocides are antimicrobials
found in surface disinfectants and household cleaners (Buffet-
Bataillon et al., 2012) that may also lead to the emergence of
AMR (Levy, 2002; Maillard, 2005; Pal et al., 2015; Webber et al.,
2015). Due to the COVID-19 pandemic, higher concentrations of
biocides are likely to be detected in wastewater treatment plants
and receiving waters. This may increase levels of AMR in the
environment, posing a human health risk for individuals exposed
to these environments. The final concentration of biocide in the
wastewater treatment plant and its receiving environments is
key. If very high, it is likely most bacteria will be completely
inhibited. This could cause significant impacts on key ecosystem
services performed by bacteria but prevent the selection for or
development of AMR. Conversely, if concentrations increase but
remain below the minimum inhibitory concentration for the
majority of bacteria present, this increase in selective pressure
could provide an opportunity for the evolution of AMR (McBain
et al., 2002). The phenomenon of sub-inhibitory selection is
comparatively well-studied for antibiotics, with significantly
fewer experimental studies on biocides. Increased antibiotic
consumption to treat or prevent secondary bacterial infections
in COVID-19 patients, or as a potential therapy for COVID-
19, will also result in increased concentrations of antibiotics
in the wastewater system and receiving environments. Again,
this increased selective pressure may result in selection for
AMR. However, unlike with biocides, it is highly doubtful that
completely inhibitory concentrations of antibiotics could be
reached, due to metabolism by the patient and a greater dilution
factor. Furthermore, it has been shown previously that low
concentrations of antibiotics can select for AMR just as much
as high, clinically relevant concentrations (Murray et al., 2018).
These increased concentrations of biocides and antibiotics in
wastewater as a result of the COVID-19 pandemic and their
impacts would form an interesting area of research.
Significant reductions in travel (in addition to resulting in a
much-needed reduction in carbon dioxide emissions) will also
have impacts for the spread of AMR. Movement of key AMR
genes between countries in undeniable. For example, one of
the key genes conferring resistance to last resort carbapenem
antibiotics (NDM-1) was first isolated in India (Liang et al., 2011),
and has since been detected worldwide (Nordmann et al., 2011).
Similarly, emergence of the mcr1 gene that confers resistance
to another last resort antibiotic, colistin, was first detected in
China (Liu et al., 2016) but has since been found worldwide
(Castanheira et al., 2016). Transferable tigecycline resistance
gene tet(X4) was also detected in China for the first time
last year (Bai et al., 2019). The CTX-M genes originated in
environmental bacteria (Humeniuk et al., 2002; Olson et al.,
2005; Cantón et al., 2012) but have since been labeled a
“pandemic” (Canton and Coque, 2006). Whilst a viral pandemic
has the more immediate outcome of infection, often with
symptoms, transmission of AMR may result in infection, or
colonization and shedding. For example, it has been shown
that following travel to countries with high rates of AMR,
travelers can become colonized by new AMR genes or bacteria.
Following travel to China, India or northern Africa, colonization
of Swedish travelers with extended-spectrum beta-lactamase
producing Enterobacteriaceae increased from 2.4 to 68%, and this
took weeks to months (and up to 1 year) to return to a pre-
travel level (ÖstholmBalkhed et al., 2018). Reduction of travel
on such a massive scale should have also slowed the spread
of AMR.
Public Awareness
There is no denying the understandably extensivemedia coverage
of the COVID-19 pandemic. In particular, how the outbreak
has crossed international borders so rapidly to become the
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current crisis facing all countries. AMR has been reportedly
described as a problem that “knows no borders.” According
the WHO, the definition of a pandemic is human-to-human
spread of microorganisms and community-level outbreaks in
three countries, one of which must be within a different WHO
region (WHO, 2009). Arguably, AMR can also be considered
as a pandemic, although a more insidious one that has fewer
immediate effects on everyday life but potentially more far
reaching negative impacts. According to the European Center
for Disease Control and Prevention, at the time of writing,
190, 236 lives have sadly been lost to COVID-19 globally over
the past 4 months (ECDC, 2020). AMR currently kills an
estimated 700, 000 people each year (IACG, 2019). For a crude
comparison, assuming both figures are accurate estimates and
COVID-19 death rates remain constant for the remainder of
the year, AMR will result in 130,000 more deaths this year
alone. In addition, AMR deaths are predicted to increase to
10 million deaths per year by 2050 (O’Neill, 2014), whereas
it is hoped COVID-19 can be managed in a much shorter
time frame.
In future, COVID-19 may be a useful comparison for
describing the spread of AMR and highlighting how difficult
it is to control, once it has emerged. According to a study
performed by theWHO, a very commonmisconception amongst
the public is that antibiotics can be used for viral infections
(i.e., the common cold) (WHO, 2015). Media coverage of the
COVID-19 outbreak has highlighted there is no “cure” for
infection, often stating antibiotics are ineffective and antiviral
treatments are being trialed in certain countries. Using terms like
“antiviral” may also help with understanding there are different
medications for different types of infection. Furthermore, people
who are self-isolating due to suspected or confirmed infection
with COVID-19 may have previously asked for antibiotics. If
they have adhered to the self-isolation protocol, they would
not have been able to visit their family doctor to request such
a prescription. It is possible that the public may now have
greater awareness of suitable use of antibiotics, which should
be capitalized on once the outbreak has been controlled. A
long-term, potential benefit could be reduced antibiotic use
that should be considered when discussing potential antibiotic
therapies for COVID-19. Repeating studies that examine public
understanding of appropriate antibiotic use, such as the one
above, would be useful to see if the outbreak has caused a shift
in public awareness of AMR.
Conclusions
Potential implications, both good and bad, of some of the
current management practices and practicalities of managing
the novel coronavirus outbreak in relation to AMR have
been discussed. This is by no means a comprehensive list
and without doubt, further impacts will become apparent
as the situation rapidly progresses. This pandemic will
be considered a significant event in human history. Both
emerging infectious diseases and AMR are included in the
UK government’s National Risk Registry of Civil Emergencies
(HM Government, 2017). The global issue of AMR will persist
beyond the COVID-19 outbreak, and understanding some
of the impacts the management strategies employed globally
had, or will have, on AMR in the clinic, the environment
and regarding public awareness should be investigated, when
the time is right. In the mean time, everyone should wash
their hands.
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